Kyntra Bio (FRA:1FG0) Cyclically Adjusted Book per Share: €71.81 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:1FG0 Kyntra Bio Inc FRA:1FG0
53 GF Score
Price €6.40
GF Value €3.97
Valuation Significantly Overvalued
! 9 Warning Signs
View Full Analysis

What is Kyntra Bio Cyclically Adjusted Book per Share?

Kyntra Bio FRA:1FG0 -0.78% 53 Cyclically Adjusted Book per Share is €71.81 as of Jun. 2026. GuruFocus rates FRA:1FG0 with a GF Score™ of 53/100 and a GF Value™ of €3.97 (Significantly Overvalued). The stock has 9 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Kyntra Bio's adjusted book value per share for the three months ended in Jun. 2026 was €-1.759. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €71.81 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Kyntra Bio's average Cyclically Adjusted Book Growth Rate was -10.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

As of today (2026-09-18), Kyntra Bio's current stock price is €6.40. Kyntra Bio's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 was €71.81. Kyntra Bio's Cyclically Adjusted PB Ratio of today is 0.09.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Kyntra Bio was 5.69. The lowest was 0.06. And the median was 0.13.


Kyntra Bio  (FRA:1FG0) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Kyntra Bio's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=6.40/71.814
=0.09

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Kyntra Bio was 5.69. The lowest was 0.06. And the median was 0.13.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Kyntra Bio Cyclically Adjusted Book per Share Related Terms


Kyntra Bio Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Kyntra Bio's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kyntra Bio Cyclically Adjusted Book per Share Chart

Kyntra Bio Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 67.22 85.11 92.55 79.51 71.72

Kyntra Bio Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 79.41 77.10 74.44 73.66 71.81

FRA:1FG0 vs IGC, ATNM, NNVC: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Kyntra Bio's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kyntra Bio Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kyntra Bio's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Kyntra Bio's Cyclically Adjusted PB Ratio falls into.


FRA:1FG0
53GF Score
Kyntra Bio Inc FRA:1FG0
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kyntra Bio Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Kyntra Bio's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book= Book Value per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=-1.759/333.9520*333.9520
=-1.759

Current CPI (Jun. 2026) = 333.9520.

Kyntra Bio Quarterly Data

Book Value per Share CPI Adj_Book
201609 69.697 241.428 96.407
201612 65.192 241.432 90.174
201703 54.777 243.801 75.032
201706 77.019 244.955 105.002
201709 152.700 246.819 206.607
201712 138.229 246.524 187.251
201803 126.416 249.554 169.169
201806 130.942 251.989 173.533
201809 124.450 252.439 164.635
201812 135.281 251.233 179.823
201903 131.447 254.202 172.685
201906 163.876 256.143 213.657
201909 161.374 256.759 209.890
201912 136.034 256.974 176.784
202003 122.418 258.115 158.386
202006 102.414 257.797 132.668
202009 110.468 260.280 141.736
202012 98.641 260.474 126.467
202103 90.156 264.877 113.667
202106 63.704 271.696 78.301
202109 80.289 274.310 97.746
202112 54.229 278.802 64.956
202203 42.876 287.504 49.803
202206 31.570 296.311 35.580
202209 12.571 296.808 14.144
202212 -0.368 296.797 -0.414
202303 -6.879 301.836 -7.611
202306 -14.072 305.109 -15.402
202309 -27.662 307.789 -30.013
202312 -37.165 306.746 -40.461
202403 -43.319 312.332 -46.318
202406 -44.230 314.175 -47.014
202409 -44.836 315.301 -47.488
202412 -43.932 315.605 -46.486
202503 -40.067 319.799 -41.840
202506 -38.136 322.561 -39.483
202509 3.678 324.800 3.782
202512 0.942 324.054 0.971
202603 -1.992 330.213 -2.015
202606 -1.759 333.952 -1.759

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of €71.81 mean?
Kyntra Bio (FRA:1FG0) has a Cyclically Adjusted Book per Share of €71.81 as of Jun. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Kyntra Bio and its competitors.
Is Kyntra Bio's Cyclically Adjusted Book per Share too high?
Kyntra Bio's current Cyclically Adjusted Book per Share is €71.81. Overall, Kyntra Bio has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Kyntra Bio's Cyclically Adjusted Book per Share compare to IGC and ATNM?
Kyntra Bio's Cyclically Adjusted Book per Share of €71.81 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Kyntra Bio and its competitors. Kyntra Bio's current Cyclically Adjusted Book per Share is €71.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kyntra Bio stock overvalued right now?
Based on GuruFocus' analysis, Kyntra Bio (FRA:1FG0) is currently considered Significantly Overvalued. The stock's GF Value™ is €3.97, compared to a current price of €6.40 — trading 61.2% above its estimated fair value. The current Cyclically Adjusted Book per Share is €71.81. Kyntra Bio's overall GF Score™ is 53/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Kyntra Bio (FRA:1FG0), the current Cyclically Adjusted Book per Share is €71.81 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Kyntra Bio (FRA:1FG0) Overvalued in 2026?

Based on GuruFocus' analysis, Kyntra Bio stock appears to be overvalued. The current stock price of €6.40 is trading 61.2% above its estimated GF Value™ of €3.97. GuruFocus considers Kyntra Bio to be Significantly Overvalued.

Key valuation signals for FRA:1FG0:

  • Cyclically Adjusted Book per Share: €71.81
  • GF Value™: €3.97 vs. price of €6.40 (61.2% above fair value)
  • GF Score™: 53/100 with 9 warning signs

No single metric tells the full story. See the FRA:1FG0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Kyntra Bio Business Description

Other Exchanges KYNB:USAKYNB:Mexico0IL8:UK
Address 350 Bay Street, Suite 100, No. 6009, San Francisco, CA, USA, 94133
Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC). Itd pipeline drug candidates include Roxadustat and FG-3246.
53GF Score

Get the complete analysis for FRA:1FG0

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€6.40
Price
€3.97
GF Value